Congenital Diaphragmatic Hernia Drugs Market Trends, Top Companies, Share, Growth And Forecast 2033 


The congenital diaphragmatic hernia drugs market size has grown strongly in recent years. It will grow from $4.04 billion in 2023 to $4.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to high incidence of congenital diaphragmatic hernia cases, increasing awareness of congenital diaphragmatic hernia, government initiatives.

The congenital diaphragmatic hernia drugs market size is expected to see strong growth in the next few years. It will grow to $5.84 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing healthcare expenditure, rare disease incentives, growing patient advocacy groups, regenerative medicine, targeted therapies. Major trends in the forecast period include advancements in medical research, advancements in drug development, advances in fetal surgery, pharmacological lung growth, increasing use of personalized medicine, development of new and innovative drug delivery systems, digital health technologies.

Market Overview -
Congenital diaphragmatic hernia (CDH) is a rare condition that occurs when there is a hole in the diaphragm, the muscle that separates the chest from the abdomen. Congenital diaphragmatic hernia (CDH) drugs refer to the medications used in the treatment of Congenital diaphragmatic hernia and help reduce the severity of the disease and manage the symptoms and complications associated with the disease.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=12928&type=smp

Elevated Birth Defect Rates Fuel Growth In The Congenital Diaphragmatic Hernia Drug Market
The rising birth defects rate is expected to propel the growth of the congenital diaphragmatic hernia drug market. Birth defects refer to structural or functional abnormalities present at birth that can affect the baby's overall health and development. The treatment for congenital diaphragmatic hernia provides prenatal screening, genetic counseling and targeted therapies that lower the occurrence of birth defects due to congenital diaphragmatic hernia and improve the potential for early intervention and personalized care, enhancing the overall well-being and quality of life of affected individuals. For instance, in March 2023, according to the World Health Organization (WHO), a US-based intergovernmental organization, annually, approximately 8 million infants are born with birth defects, with low- and middle-income nations accounting for 9 out of 10 significant problems. Further, an estimated 240,000 newborns die worldwide within 28 days of birth each year due to congenital disorders. Therefore, the rising birth defect rate drives the congenital diaphragmatic hernia drug market.

Competitive Landscape -
Major players in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Amgen Inc., Becton, Dickinson and Company, Viatris Inc., B. Braun SE, Sun Pharmaceutical Industries Ltd., C.R. Bard Inc., W. L. Gore & Associates, Chiesi Farmaceutici S.p.A., Getinge AB, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals, Integra LifeSciences Corporation, Genentech Inc., LifeCell International Private Limited, Cook Biotech Inc., Cousin Biotech SAS, Dipro Medical Devices S.R.L., Aspide Medical.

Innovative Coating Technology Revolutionizes Congenital Diaphragmatic Hernia Treatment
Major companies operating in the congenital diaphragmatic hernia (CDH) market are introducing advancements in treatment procedures with coating technology to sustain their position in the market. Coating technology for drug-embedded synthetic hernia mesh involves the application of a specialized layer or coating onto the surface of a synthetic mesh used for hernia repair. For instance, in April 2022, Ariste Medical, a US-based pre-commercial drug and device company, received U.S. Food and Drug Administration (FDA) clearance to market its drug-embedded synthetic hernia mesh, which aims to reduce the risk of microbial colonization during surgical implantation. The mesh combines the benefits of polypropylene mesh with a biocompatible coating that allows antibiotic residence to mitigate bacterial colonization. This coating technology can be used for implantable and non-implantable devices and has shown potential in materials like polyurethane and ePTFE. Ariste Medical's coating technology could also be applied to ePTFE surgical implants, such as hernia repair surgeries.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Key Segments -

The congenital diaphragmatic hernia drugs market covered in this report is segmented -

1) By Type: Posterolateral Bochdalek Hernia; Anterior Morgagni Hernia; Hiatal Hernia
2) By Treatment: Extracorporeal Membrane Oxygenation; Other Treatments
3) By Diagnosis: Prenatal; Postnatal
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.